S100A10, a novel biomarker in pancreatic ductal adenocarcinoma
Pancreatic cancer is arguably the deadliest cancer type. The efficacy of current therapies is often hindered by the inability to predict patient outcome. As such, the development of tools for early detection and risk prediction is key for improving outcome and quality of life. Here, we introduce the...
Main Authors: | Moamen Bydoun, Andra Sterea, Henry Liptay, Andrea Uzans, Weei‐Yuarn Huang, Gloria J. Rodrigues, Ian C.G. Weaver, Hong Gu, David M. Waisman |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-11-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12356 |
Similar Items
-
Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma
by: Hong-Bin Li, et al.
Published: (2021-09-01) -
Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma
by: Wen-Jing Liu, et al.
Published: (2018-01-01) -
Targeting mTOR in Pancreatic Ductal Adenocarcinoma
by: Sentia eIriana, et al.
Published: (2016-04-01) -
Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
by: Prashanth Ashok Kumar, et al.
Published: (2023-06-01) -
Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
by: Yixuan Ma, et al.
Published: (2022-09-01)